[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"in-vitro-fertilization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:in-vitro-fertilization":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,52,86,113,148,178,207,232,258,289,316,341],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641313","hippo-related-competing-endogenous-rna-cerna-network-dysregulation-and-in-vitro-fertilization-ivf-outcomes-in-women-with-diminished-ovarian-reserve-100641313",false,"NCT07658846","Hippo-Related Competing Endogenous RNA (ceRNA) Network Dysregulation and In Vitro Fertilization (IVF) Outcomes in Women With Diminished Ovarian Reserve","Investigating the Dysregulation of the Hippo-Related ceRNA Network and Its Impact on IVF Outcomes in Patients With Diminished Ovarian Reserve (DOR)","DOR-HIPPO-IVF","Inclusion Criteria:\n\n* Women undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycles.\n* Infertility duration of at least one year\n* Primary or secondary infertility.\n\nExclusion Criteria:\n\n* Polycystic Ovary Syndrome (PCOS)\n* Endometriosis.\n* Ovarian tumors or malignancy.\n* Severe systemic diseases affecting fertility.\n* Metabolic syndrome.\n* Connective tissue disorders.\n* Hormonal therapy within the last three months.\n* Refusal to participate.","FEMALE","18 Years","40 Years",{"count":21,"type":22},70,"ESTIMATED","OBSERVATIONAL","Diminished Ovarian Reserve (DOR) is an important cause of female infertility and is associated with poor ovarian response and lower pregnancy rates during In Vitro Fertilization (IVF). The molecular mechanisms underlying impaired follicular development in DOR remain incompletely understood. Increasing evidence suggests that non-coding RNAs and components of the Hippo signaling pathway play important roles in granulosa cell proliferation, apoptosis, and follicular development.\n\nThis prospective observational cohort study aims to investigate the expression of the long non-coding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), microRNA (miRNA)-181a-5p, Hippo pathway components including Yes-Associated Protein 1 (YAP1) and Connective Tissue Growth Factor (CTGF), and Insulin-Like Growth Factor 1 (IGF1) in follicular fluid-derived cells from women with DOR undergoing IVF compared with women with normal ovarian reserve. The study will also evaluate relationships among these molecular markers and IVF outcomes, including oocyte quality, number of retrieved oocytes, and embryo developmental potential.",[26,27,28],"Diminished Ovarian Reserve","Female Infertility","In Vitro Fertilization",[30,31,32,33,34,35,36,37,38],"Diminished Ovarian Reserve (DOR)","In Vitro Fertilization (IVF)","Hippo Signaling Pathway","Nuclear Paraspeckle Assembly Transcript 1 (NEAT1)","microRNA-181a-5p","Yes-Associated Protein 1 (YAP1)","Connective Tissue Growth Factor (CTGF)","Insulin-Like Growth Factor 1 (IGF1)","Follicular Fluid","NOT_YET_RECRUITING","2026-06-17",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":22},"2026-08-01",{"date":47,"type":22},"2028-10-01",{"name":49,"class":50},"Assiut University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":51},"100631412","day-4-embryo-defragmentation-blastocyst-rate-and-clinical-outcomes-100631412","NCT07500337","Day-4 Embryo Defragmentation: Blastocyst Rate and clInical Outcomes","Effect of Embryo Defragmentation on Day 4 (D4) on Blastocyst Development Rate and Clinical Outcomes in ART Cycles: a Prospective RCT","DEBRIS","Inclusion Criteria:\n\n1. Female patients undergoing ICSI cycles at the participating center\n2. Age 18-42 years\n3. Presence of at least one morula with cytoplasmic fragmentation ≥10% at Day 4 morphological assessment (Grade B: 10-25%, Grade C: 26-50%, Grade D: ≥50%)\n4. Embryos intended for extended culture to blastocyst stage (Day 5\u002FDay 6)\n5. All embryo cultures performed in time-lapse incubator (Geri, Genea Biomedex)\n6. Written informed consent obtained prior to any study-related procedure -\n\nExclusion Criteria:\n\n1. Severely reduced ovarian reserve (AMH ≤ 0.5 ng\u002FmL)\n2. Body mass index (BMI) ≥ 32 kg\u002Fm²\n3. Diagnosis of endometriosis\n4. Polycystic ovary syndrome (PCOS)\n5. Maternal age ≥ 42 years\n6. History of repeated implantation failure\n7. Donor gamete cycles (oocyte or sperm donation)\n8. Cycles with preimplantation genetic testing for monogenic disease (PGT-M) as primary indication\n9. Embryos with severe morphological compromise at Day 3\n10. Concurrent participation in other interventional studies that could interfere with study outcomes\n11. Inability to provide written informed consent","20 Years","42 Years",{"count":63,"type":22},320,"INTERVENTIONAL",[66],"NA","Background:\n\nEmbryo fragmentation is one of the main morphological parameters assessed during in vitro culture in assisted reproductive technology (ART). The presence of anucleate cytoplasmic fragments is commonly observed in human embryos and may negatively affect developmental potential and clinical outcomes. Embryo defragmentation at early stages (Day 2-3) is an established technique in some centers, but evidence remains heterogeneous. Defragmentation at Day 4 (morula\u002Fcompaction stage) represents a significantly less explored area, with promising but insufficient data to guide clinical practice.\n\nStudy Objective:\n\nThis study aims to evaluate whether mechanical or laser-assisted embryo defragmentation performed on Day 4 (D4) of in vitro culture improves blastocyst development rates and clinical outcomes in ART cycles, compared to standard culture without intervention.\n\nStudy Design:\n\nThis is a prospective, randomized controlled trial (RCT) with single-blind assessment. Patients undergoing IVF\u002FICSI with embryos showing ≥10% fragmentation at D4 morphological evaluation will be randomly assigned (1:1 ratio) to one of two groups:\n\nGroup A (Intervention): Mechanical\u002Flaser defragmentation at D4, followed by standard blastocyst culture Group B (Control): Standard blastocyst culture without any additional manipulation\n\nRandomization will be performed at the patient level using pre-generated block randomization lists, stratified by patient age (\\\u003C35 vs. ≥35 years), number of fragmented embryos at D4, and use of preimplantation genetic testing (PGT-A).\n\nParticipants:\n\nWomen aged 18-43 years undergoing IVF\u002FICSI cycles, with at least one embryo showing ≥10% fragmentation at D4 and destined for blastocyst culture. Key exclusion criteria include: donor gamete cycles, PGT-M as primary indication, embryos with \\>50% fragmentation, or severe morphological compromise at Day 3.\n\nPrimary Outcome:\n\nRate of usable blastocysts (Gardner score ≥3BB) per embryo included in the study, assessed at Day 5 and Day 6 of culture.\n\nSecondary Outcomes:\n\nOverall blastocyst development rate (D5\u002FD6), Gardner score distribution, blastocyst cryopreservation rate, implantation rate, clinical pregnancy rate (heartbeat at 7 weeks), ongoing pregnancy rate (beyond 12 weeks), live birth rate per transfer, and morphokinetic analysis (if time-lapse incubator available).\n\nSample Size:\n\nApproximately 240 patients total (120 per arm), based on an expected blastocyst rate of \\~42% in the control group vs. \\~57% in the intervention group (15% absolute difference), with 80% power and α=0.05. A 15% dropout correction is applied.\n\nDuration:\n\n6 months of enrollment plus 6 months of clinical follow-up (total \\~12 months).",[27,69,28],"Embryo Development",[71,72,73,74,75,76],"Embryo defragmentation","Blastocyst development","Embryo fragmentation","ICSI","Embryo culture","Randomized controlled trial","RECRUITING","2026-03-24",{"date":80,"type":43},"2026-03-30",{"date":78,"type":43},{"date":83,"type":22},"2026-12-31",{"name":85,"class":50},"Momo Fertilife",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":51},"100615806","mechanisms-of-maternal-immune-tolerance-in-early-pregnancy-100615806","NCT07297394","Mechanisms of Maternal Immune Tolerance in Early Pregnancy","Inclusion Criteria:\n\nBlood from patients will be included before and during pregnancies (or failed implantation) conceived through IVF\u002FICSI (Intracytoplasmic Sperm Injection) treatment and in case of miscarriage.\n\n1. where the patient (pregnant person) was ≥ 18 years of age.\n2. where the patient (pregnant person) signed a written informed consent.\n\nExclusion Criteria:\n\n1. Certain maternal infections (HIV, Hepatitis B, Hepatitis C, Syphilis)\n2. Patients under immunosuppressive medications (at time of blood sample collection)",{"count":93,"type":22},100,"This study explores the mechanisms of maternal immune tolerance in early pregnancy by characterizing immune cell profiles and functional pathways during the first trimester. The goal is to identify immunological factors that support healthy gestation and prevent complications such as miscarriages.",[96,97,28],"Pregnancy","Immune Tolerance",[99,100,101,102,103],"Maternal Immune Tolerance","Early Pregnancy","Immune Regulation","T cells","Cytokines","2026-03-03",{"date":106,"type":43},"2026-03-04",{"date":108,"type":43},"2026-03-02",{"date":110,"type":22},"2030-12",{"name":112,"class":50},"University Hospital, Basel, Switzerland",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":64,"phases":122,"briefSummary":123,"conditions":124,"keywords":132,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":51},"100624916","the-effect-of-a-four-week-hatha-yoga-intervention-to-improve-quality-of-life-anxiety-and-depressive-symptoms-in-individuals-undergoing-assisted-reproductive-technology-art-treatment-100624916","NCT07415850","The Effect of a Four-Week Hatha Yoga Intervention to Improve Quality of Life, Anxiety, and Depressive Symptoms in Individuals Undergoing Assisted Reproductive Technology (ART) Treatment","The Effect of a Four-Week Hatha Yoga Intervention to Improve Quality of Life, Anxiety, and Depressive Symptoms in Individuals Undergoing Assisted Reproductive Technology (ART) Treatment: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years of age or older\n* Understand English\n* Scheduled for or currently undergoing an IVF cycle\n* Access to smartphone\u002Fcomputer\u002Ftablet and internet\n* Have a valid working email address\n\nExclusion Criteria:\n\n* Individuals who are Pregnant, or who become Pregnant during the study\n* Individuals undergoing non-IVF cycles (i.e. intrauterine insemination)\n* Individuals undergoing a frozen embryo transfer (FET) cycle\n* Individuals who are currently regularly practicing yoga\n* Individuals who score in the \"severe depression\" classification on the PHQ-9 (PHQ-9 score of 20-27)\n* Individuals endorsing suicidal ideation (answering yes on #9 of PHQ-9).",{"count":121,"type":22},80,[66],"The goal of this clinical trial is to learn if a four-week yoga program works to improve quality of life in people undergoing IVF (In Vitro Fertilization). It will also learn if a four-week yoga program decreases anxiety and depression symptoms in people undergoing IVF.\n\nThe main questions it aims to answer are:\n\n* Does a four-week yoga program effect quality of life, anxiety, and depression symptoms in people undergoing IVF?\n* Do the effects vary by individual characteristics of the people in the study?\n\nResearchers will compare the yoga intervention group to routine care as usual.\n\nParticipants will:\n\n* Participate in a weekly virtual yoga class for four weeks (total of four yoga classes), or follow routine care as usual while undergoing IVF.\n* Take three online surveys every 4 weeks.\n* Be involved in the study for 8 weeks.",[125,28,126,127,128,129,130,131],"IVF","Quality of Life (QOL)","Anxiety","Depression and Anxiety Symptom","Assisted Reproduction Technologies","Yoga","Mental Health",[133,134,135,136,130,137,138],"Fertilization in Vitro","Reproductive Techniques, Assisted","Quality of Life","Psychological Well-Being","Mind-Body Therapies","Complementary Therapies","2026-02-09",{"date":141,"type":43},"2026-02-17",{"date":143,"type":22},"2026-01-21",{"date":145,"type":22},"2027-01-31",{"name":147,"class":50},"Villanova University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":64,"phases":159,"briefSummary":161,"conditions":162,"keywords":164,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":51},"100527664","phase-3-luteal-phase-support-with-gnrh-agonist-after-gnrh-agonist-triggering-in-ivficsi-cycles-100527664","NCT06150703","Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF\u002FICSI Cycles","Luteal Phase Support With GnRH Agonist Alone After GnRH Agonist Triggering and Fresh Embryo Transfer Compared to the Reference Protocol (hCG Triggering and Progesterone Luteal Support): a Randomised Controlled Trial","SOLOAGO","Inclusion Criteria:\n\n* Patients requiring conventional IVF or IVF with sperm injection (ICSI) from the partner or donor under the conditions of management defined by French law.\n* Patients aged 18 to 39 included\n* First or second attempt at IVF or ICSI for pregnancy\n* BMI \\\u003C 35 kg\u002Fm2\n* Anti-Mullerian hormone (AMH) \\> 1 ng\u002Fml (= 7 pmol\u002FL) and\u002For antral follicle count ≥ 8 within the year prior to inclusion\n* AMH \\\u003C 5 ng\u002Fml and\u002For antral follicle count \\\u003C40 within the year prior to inclusion\n* Treatment with recombinant FSH\n* Antagonist protocol (with pre-treatment or not)\n* Initial dose of recombinant FSH between 75 and 450 IU\n* Signed informed consent\n* Affiliation to the social security system (excluding AME)\n\nExclusion Criteria:\n\n* Patient diagnosed with HIV infection\n* ICSI with sperm from testicular biopsy\n* Pre-implantation diagnosis\n* Hypogonadotropic hypogonadism (amenorrhea or spaniomenorrhea with basal LH \\\u003C1.2 IU\u002FL)\n* History of severe ovarian hyperstimulation syndrome (OHSS)\n* Unoperated hydrosalpinx\n* Intracavitary polyps or myomas deforming the cavity\n* Known hypersensitivity to the investigational drugs and\u002For their excipients (human chorionic gonadotropin, progesterone, nafarelin acetate, GnRH, GnRH analogues, mannitol, sodium chloride, water for injection, glacial acetic acid, Sodium hydroxide and\u002For hydrochloric acid, sorbitol, purified water, benzalkonium chloride, sunflower oil, soybean lecithin, gelatin, glycerol, titanium dioxide (E171), methionine, poloxamer 18, phosphoric acid).\n* Gynaecological bleeding or genital haemorrhage\n* History of epilepsy and\u002For intracranial tumors potentially causing epilepsy\n* Tumours of the hypothalamus or pituitary gland\n* Ovarian enlargement or cysts unrelated to polycystic ovary syndrome\n* Severe adenomyosis requiring a long protocol\n* Carcinoma of the ovary, uterus or breast\n* Active thromboembolic events\n* Severe impairment of liver function\n* Breastfeeding women\n* Patients under court protection, guardianship or curators\n* Current participation in another therapeutic interventional trial on the day of inclusion\n* Patients who do not speak or understand French","39 Years",{"count":158,"type":22},652,[160],"PHASE3","The development of stimulation protocols for in vitro fertilisation (IVF) has led to a paradox. It has now been established that obtaining a large number of oocytes is a key to success, but that it is also a risk factor for embryo transfer failure after puncture (disruption of endometrial receptivity due to luteal insufficiency) and a risk factor for complications such as ovarian hyperstimulation syndrome (OHSS).",[28,163],"ICSI Intracytoplasmic Spermatozoid Injection",[165,166,167,168],"GnRH agonist triggering","GnRH agonist luteal phase support,","pregnancy","live birth","2025-08-22",{"date":171,"type":43},"2025-08-24",{"date":173,"type":43},"2024-06-27",{"date":175,"type":22},"2027-09-27",{"name":177,"class":50},"Assistance Publique - Hôpitaux de Paris",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":64,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":51},"100575001","effect-of-super-gdf9-on-capa-ivm-of-cocs-from-small-antral-follicles-100575001","NCT06766604","Effect of Super-GDF9 on CAPA-IVM of COCs From Small Antral Follicles","Exploratory In-vitro Study Evaluating the Addition of Super-GDF9 During Capacitation-in-vitro Maturation (CAPA-IVM) of Donated Human Cumulus-oocyte Complexes (COCs) Derived From Small Antral Follicles","sGDF-9","Inclusion Criteria:\n\n1. Women between the ages of 18 and 38 years (both inclusive)\n2. BMI ≤ 32 kg\u002Fm2\n3. PCOS women according to the Rotterdam criteria (2003)\n4. Indicating CAPA-IVM treatment.\n5. Serum AMH ≥ 4 ng\u002FmL (28.57 pmol\u002FL) at screening and having at least 24 antral follicles in two ovaries by transvaginal ultrasound at the time of CAPA-IVM indication\n6. Willing to donate COCs for research purposes\n7. Agreeing for frozen embryo\n8. Signed informed consent before any study-related procedures\n\nExclusion Criteria:\n\n1. Known endometrioma or grade 3-4 endometriosis according to ASRM classification\n2. Uterine abnormalities\n3. Couples with severe male factor (sperm concentration \\\u003C5 million\u002Fml, motility \\\u003C 10%), surgical sperm retrieval.\n4. Previous history of unexplained immature oocytes after IVF treatment\n5. Cycles using donor oocytes","38 Years",{"count":188,"type":22},9,[66],"CAPA-IVM (In Vitro Maturation) technology is an assisted reproductive method offering significant benefits in terms of safety and treatment costs, particularly for high-risk patients. These include individuals with ovarian hyperstimulation syndrome (OHSS), venous thrombosis, ovarian torsion, or polycystic ovary syndrome (PCOS). However, while the live birth rate in the CAPA-IVM group (35.2%) is comparable to conventional IVF (43.2%), the number of good-quality embryos and cumulative clinical pregnancy rates remain lower. Improving the CAPA-IVM culture process, particularly through the addition of growth factors found in follicular fluid, has shown promise in enhancing oocyte quality.\n\nGrowth differentiation factor 9 (GDF9) and Bone morphogenetic protein 15 (BMP15) play critical roles in follicular development, with their heterodimer structure demonstrating the most positive effects on cumulus-oocyte complexes (COCs). Recent studies have identified a potent variant, super GDF9, which is \\>1000 times more effective than GDF9 and surpasses cumulin, a heterodimeric growth factor. Super GDF9 enhances cumulus cell expansion and oocyte developmental competence, closely mimicking in vivo maturation.\n\nThis study investigates the impact of supplementing super GDF9 during CAPA-IVM culture, aiming to improve outcomes of cumulus-oocyte complexes (COCs) from small follicles and ultimately enhance treatment success.",[28],[193,194,195,196,197],"CAPA-IVM","super-GDF9","Culture","OSFs","PCOS","2025-07-09",{"date":200,"type":43},"2025-07-10",{"date":202,"type":43},"2025-01-10",{"date":204,"type":22},"2026-04-30",{"name":206,"class":50},"Mỹ Đức Hospital",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":214,"sex":17,"minAge":18,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":64,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":230,"locationsCount":51},"100594522","ovarian-prp-injections-for-improved-embryo-quality-using-embryo-quality-score-100594522","NCT07020546","Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score","Ovarian Platelet-Rich Plasma (oPRP) Injections Improvement In IVF Patients Based On Time-Lapse Incubator Culture for Automated Tracking and AI for Embryo Quality Assessment : A Non-Randomized Propsective Self-Controlled Interventional Study","Inclusion Criteria:\n\n* No none contraindications to IVF or PRP treatment\n* Adequate ovarian reserves and AMH level\n* Willingness to undergo two IVF cycles and oPRP treatment\n\nExclusion Criteria:\n\n* Anovulation due to menopause or perimenopause\n* Any health conditions that are contraindicated for IVF or oPRP treatment",true,"47 Years",{"count":217,"type":22},180,[66],"Patients will have ovarian PRP treatments and embryo development will be observed using time-lapse imaging and AI software.",[221,222,223,224],"Infertility","Poor Ovarian Reserve","Embryo Growth Disorder","in Vitro Fertilization","2025-07-08",{"date":198,"type":43},{"date":225,"type":43},{"date":229,"type":22},"2026-08-30",{"name":231,"class":50},"Generation Next Fertility",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":17,"minAge":239,"maxAge":156,"enrollmentInfo":240,"targetDuration":4,"studyType":64,"phases":242,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":51},"100592227","phase-2-effect-of-salidroside-on-pregnancy-outcomes-in-high-childbearing-age-patients-in-viro-fertilization-100592227","NCT06990685","Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization","Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization: an Open-label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥35 and \\\u003C 40 years old\n2. For the first or second cycle of IVF, ICSI or IVF with donor sperm\n3. According to the 2016 Poseton criteria for poor prognosis: the number of oocytes obtained in the previous routine ovulation induction protocol was 1-9, or AFC \\\u003C 5 or AMH \\\u003C 1.2ng\u002Fml (measured within the past half year) in both ovaries.\n\nExclusion Criteria:\n\n1. Patients with coagulation disorders\n2. Patients with previous abnormal uterine bleeding\n3. Combined with hydrosalpinx confirmed by B-ultrasound and HSG\n4. Uterine malformation (unicornuate uterus, septate uterus) or history of intrauterine adhesions\n5. Patients with previous spontaneous abortion ≥3 times\n6. Patients with contraindications to assisted reproductive technology or pregnancy\n7. Previous or current oral medication containing salidroside\n8. The controlled ovarian stimulation protocol included PPOS protocol, luteal phase ovulation induction protocol, and continuous stimulation protocol","35 Years",{"count":241,"type":22},370,[243],"PHASE2","With the decreasing of birth rate and population in our country, population problem has become a long-term and strategic problem. In addition to the decrease in the number of women of childbearing age and the impact of unmarried women, the increase in the incidence of reproductive disorders and the delay of marriage and childbearing are also important factors leading to the continuous decline of the birth population in China. Among them, ovarian aging is a key factor causing female fertility difficulties. Therefore, establishing an effective prevention and treatment strategy for ovarian aging is of great significance for improving female reproductive health and serving the national population strategy. Recently, several supplements have been found to promote folliculogenesis and improve oocyte quality. However, to date, there is no approved therapeutic agent for the treatment of ovarian aging. Therefore, it is urgent to develop effective strategies for the prevention and treatment of ovarian aging.\n\nSalidroside is the main active component of Chinese medicine Rhodiola, and its content is highest in the root of rhodiola, which is also the main medicinal part. The main efficacy of salidroside in traditional Chinese medicine is to benefit qi, promote blood circulation, unblock pulse and relieve asthma. At the same time, in basic research, more and more experiments have shown that salidroside has a variety of pharmacological properties, including anti-hypoxia, anti-fatigue and anti-aging effects, anti-cancer, anti-inflammatory, anti-oxidation, antiviral and so on. These pharmacological effects suggest that salidroside may be an effective drug for the prevention and treatment of atherosclerosis, Parkinson's disease, Alzheimer's disease, pneumonia and other diseases. In terms of aging, it has been confirmed that salidroside supplementation can prolong the life span of pseudogill oryzias zhan and rescue premature aging of human skin fibroblasts, etc., which further confirms.\n\nThe aim of this study is to investigate the efficacy of salidroside as an adjuvant drug in improving the pregnancy outcomes of fresh embryo transfer in high childbearing age patients with poor ovarian response by comparing the pregnancy outcomes of fresh embryo transfer between salidroside group and blank control group. This pragmatic clinical study is expected to improve pregnancy outcomes of fresh embryo transfer cycles in women of advanced childbearing age with poor ovarian response.",[246,247,28,248],"Salidroside","Randomized Controlled Trial","Assisted Reproductive Technology","2025-05-22",{"date":251,"type":43},"2025-05-25",{"date":253,"type":22},"2025-06-01",{"date":255,"type":22},"2027-12",{"name":257,"class":50},"The Second Hospital of Shandong University",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":214,"sex":266,"minAge":18,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":64,"phases":270,"briefSummary":271,"conditions":272,"keywords":273,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":51},"100536195","effect-of-antioxydant-enriched-media-on-blastocyst-euploidy-rates-100536195","NCT06261671","Effect of Antioxydant-enriched Media on Blastocyst Euploidy Rates.","Antioxidants-enriched Single-step vs Global Total Single-step Embryo Culture Media: Effect on Blastocyst Euploidy Rates.","GX","Inclusion Criteria:\n\n* Patients undergoing assisted reproductive technology cycles when ICSI is indicated.\n* Patients when Iin vitto fertilization (IVF) is also performed will be included as far as there are enough oocytes for ICSI randomization. However, IVF oocytes will not be used for the study.\n* Maternal age 18-43 years old.\n* PGT-A cycles with only trophectoderm biopsies on day 5\u002F6\u002F7.\n* Patients with more than 6 COCs expected for ICSI.\n* Body mass index \\\u003C35.\n* Fresh and frozen ejaculated sperm.\n\nExclusion Criteria:\n\n* PGT-M cycles\n* Fresh and frozen testicular sperm.","ALL","43 Years",{"count":269,"type":22},500,[66],"One of the most sensible factors in IVF culture conditions is the susceptibility of gametes and embryos to an induced increase in reactive oxidative species (ROS) caused by the artificial environment. This study aims to evaluate the impact of using antioxidant-supplemented media during culture to evaluate embryo ploidy rates in a prospective randomized trial using sibling oocytes.",[221,28],[274,275,276,277,278,279],"Intracytoplasmic sperm injection","Pre - implanttaion genetic diagnosis for aneuploidy","Antioxydante","Culture media","Embryo development","Euploidy","2025-02-20",{"date":282,"type":43},"2025-02-21",{"date":284,"type":43},"2024-02-01",{"date":286,"type":22},"2025-12-31",{"name":288,"class":50},"ART Fertility Clinics LLC",{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":64,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":51},"100564093","exploring-the-effect-of-footbaths-on-increasing-the-success-rates-in-vitro-fertilization-100564093","NCT06624683","Exploring the Effect of Footbaths on Increasing the Success Rates in Vitro Fertilization","Exploring the Effect of Footbaths on Increasing the Success Rates of in Vitro Fertilization and Its Associated Mechanism","Inclusion Criteria:\n\n* women aged 18\\~45 years\n* diagnosed with male factor infertility\n* tubal factor infertility, or unexplained infertility, and undergoing an IVF treatment.\n\nExclusion Criteria:\n\n* participants having adenomyosis, severe endometriosis\n* a history of more than two IVF treatments\n* any comorbidity or uncontrolled systemic diseases such as hypertension, diabetes, chronic heart disease or chronic renal disease that can affect the treatment process.","45 Years",{"count":121,"type":22},[66],"To evaluate the effectiveness of warm-water footbaths in enhancing pregnancy rates during IVF and to explore the underlying mechanisms involved.",[221,28],[221,302,303,304,305,306],"In vitro fertilization","Stress","Sleep quality","Inflammation","Footbath","2024-10-02",{"date":309,"type":43},"2024-10-03",{"date":311,"type":22},"2024-10",{"date":313,"type":22},"2025-10",{"name":315,"class":50},"National Taipei University of Nursing and Health Sciences",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":214,"sex":17,"minAge":323,"maxAge":61,"enrollmentInfo":324,"targetDuration":4,"studyType":64,"phases":326,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":51},"100556197","effectiveness-of-cbt-in-improving-psycho-neuro-endocrine-factors-in-women-following-in-vitro-fertilization-program-100556197","NCT06521957","Effectiveness of CBT in Improving Psycho-Neuro-Endocrine Factors in Women Following In Vitro Fertilization Program","The Effectiveness of Cognitive Behavioral Therapy in Improving Psycho-Neuro-Endocrine Factors in Women Following In Vitro Fertilization Program","Inclusion Criteria:\n\n* Women with primary infertility\n* Aged 25-42 at the start of the study\n* Willing to participate in the study and willing to sign informed consent form\n* Minimum education of high school, able to read, write and understand Bahasa Indonesia\n\nExclusion Criteria:\n\n* Having one or multiple psychotic disorder(s)","25 Years",{"count":325,"type":22},75,[66],"The goal of this clinical trial is to learn if Cognitive Behavioral Therapy (CBT) can improve psychological, neurological, and hormonal aspects in women undergoing In Vitro Fertilization (IVF). The main questions it aims to answer are:\n\n* Is CBT effective in improving psychological aspects (anxiety, depression, and coping mechanism) in women undergoing IVF?\n* Is CBT effective in improving neuroendocrine aspects (cortisol levels, neuroepinephrine levels, free trioodothyronine levels) in women underoing IVF?\n\nResearchers will compare CBT to no intervention to see if CBT is effective in improving psychoneuroendocrine aspects.",[329,330,28],"Cognitive Behavioral Therapy","Hormone Disturbance",[329,332,28],"Psycho-Neuro-Endocrine","2024-07-23",{"date":335,"type":43},"2024-07-26",{"date":337,"type":43},"2023-07-05",{"date":253,"type":22},{"name":340,"class":50},"Fakultas Kedokteran Universitas Indonesia",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":214,"sex":17,"minAge":60,"maxAge":19,"enrollmentInfo":349,"targetDuration":4,"studyType":64,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":51},"100521059","effect-of-metformin-on-healthy-live-birth-in-women-with-prediabetes-100521059","NCT06064669","Effect of Metformin on Healthy Live Birth in Women With Prediabetes","Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial","MELT-PreDM","Inclusion Criteria:\n\n1. Women who are diagnosed with prediabetes by ADA criteria, including either IFG, IGT, or HbA1C 5.7-6.4%.\n2. Women aged 20-40 years.\n3. Women who plan to undergo a new cycle of IVF, ICSI, or PGT-A.\n\nExclusion Criteria:\n\n1. Women who are diagnosed with diabetes according to the ADA criteria11,12, which is meeting one of the following criteria: fasting plasma glucose ≥7.0mmol\u002FL, 2-h plasma glucose during 75-g OGTT ≥11.1mmol\u002FL, HbA1c≥6.5%, or a random plasma glucose≥11.1mmol\u002FL.\n2. Women who are taking medicine that interfere with glucose metabolism, such as metformin, oral anti-diabetic agents (sulfonylureas, glinides, thiazolidinediones, α-glycosidase inhibitors, GLP-1 receptor agonist, etc.), weight loss drugs (i.e.orlistat, etc.), glucocorticoids, and growth hormones within 2 months before enrollment.\n3. Women with un-corrected hyperthyroidism or hypothyroidism.\n4. Women with congenital or acquired abnormal uterine cavity including septate uterus, unicornous uterus, uterus duplex, and intrauterine adhesions.\n5. Women with a diagnosis of adenomyosis.\n6. Women with untreated hydrosalpinx.\n7. Women who plan to undergo PGT-SR or PGT-M.\n8. Women with major medical comorbidities, such as known liver disease, known renal disease, or known significant anemia.",{"count":350,"type":22},988,[66],"To evaluate the efficacy and safety of metformin pretreatment on reproductive outcomes in infertile women with prediabetes.",[354,355,356],"Metformin","Prediabetes","In-Vitro Fertilization","2024-05-27",{"date":359,"type":43},"2024-05-29",{"date":361,"type":43},"2024-02-22",{"date":363,"type":22},"2027-12-31",{"name":365,"class":50},"Shandong University"]